The University of Southampton
University of Southampton Institutional Repository

New anticoagulants: how to deal with treatment failure and bleeding complications

New anticoagulants: how to deal with treatment failure and bleeding complications
New anticoagulants: how to deal with treatment failure and bleeding complications
Conventional anticoagulants have proven efficacy in the management of thromboembolism. Their adverse effects and a narrow therapeutic window, necessitating regular need for monitoring, however, have long been an incentive for the development of safer anticoagulants without compromising efficacy. Over the last decade or so several new parenteral and oral anticoagulants have been launched with efficacy comparable with conventional agents. From fondaparinux to its long acting derivative idraparinux, and the factor Xa inhibitor rivaroxaban to the direct thrombin inhibitor dabigatran, the advent of new anticoagulants is radically changing anticoagulation. For conventional anticoagulants, despite their shortcomings, effective methods of reversing their anticoagulant effects exist. Moreover, strategies to deal with the occurrence of fresh thrombotic events in the face of therapeutic anticoagulation with the conventional agents have also been addressed. Nevertheless, for the new anticoagulants, the optimal management of these complications remains unknown. This review explores these issues in the light of current evidence.
bleeding complications, dabigatran, new anticoagulants, rivaroxaban, treatment failure
0306-5251
593-603
Kazmi, Rashid S.
b31ef6bd-7f85-439d-ae28-8d097a7b8a41
Lwaleed, Bashir A.
e7c59131-82ad-4a14-a227-7370e91e3f21
Kazmi, Rashid S.
b31ef6bd-7f85-439d-ae28-8d097a7b8a41
Lwaleed, Bashir A.
e7c59131-82ad-4a14-a227-7370e91e3f21

Kazmi, Rashid S. and Lwaleed, Bashir A. (2011) New anticoagulants: how to deal with treatment failure and bleeding complications. British Journal of Clinical Pharmacology, 72 (4), 593-603. (doi:10.1111/j.1365-2125.2011.04060.x). (PMID:21752066)

Record type: Article

Abstract

Conventional anticoagulants have proven efficacy in the management of thromboembolism. Their adverse effects and a narrow therapeutic window, necessitating regular need for monitoring, however, have long been an incentive for the development of safer anticoagulants without compromising efficacy. Over the last decade or so several new parenteral and oral anticoagulants have been launched with efficacy comparable with conventional agents. From fondaparinux to its long acting derivative idraparinux, and the factor Xa inhibitor rivaroxaban to the direct thrombin inhibitor dabigatran, the advent of new anticoagulants is radically changing anticoagulation. For conventional anticoagulants, despite their shortcomings, effective methods of reversing their anticoagulant effects exist. Moreover, strategies to deal with the occurrence of fresh thrombotic events in the face of therapeutic anticoagulation with the conventional agents have also been addressed. Nevertheless, for the new anticoagulants, the optimal management of these complications remains unknown. This review explores these issues in the light of current evidence.

This record has no associated files available for download.

More information

e-pub ahead of print date: 9 September 2011
Published date: October 2011
Keywords: bleeding complications, dabigatran, new anticoagulants, rivaroxaban, treatment failure
Organisations: Faculty of Health Sciences

Identifiers

Local EPrints ID: 347869
URI: http://eprints.soton.ac.uk/id/eprint/347869
ISSN: 0306-5251
PURE UUID: b8a059b2-3c4a-4cea-b4a6-58e124990eee

Catalogue record

Date deposited: 31 Jan 2013 15:15
Last modified: 14 Mar 2024 12:53

Export record

Altmetrics

Contributors

Author: Rashid S. Kazmi

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×